We are live on ! Find out more
Jacobs Levy Equity Management

Jacobs Levy Equity Management Portfolio holdings

AUM $23.8B
1-Year Est. Return 25.4%
This Fund
S&P 500
This Quarter Est. Return
+10.19%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$10.2B
AUM Growth
+$2.04B
Cap. Flow
+$1.34B
Cap. Flow %
13.16%
Top 10 Hldgs %
16.92%
Holding
1,109
New
201
Increased
523
Reduced
236
Closed
122

Sector Composition

Rank Sector Weight
1 Technology 19.58%
2 Financials 15.64%
3 Healthcare 14.3%
4 Consumer Discretionary 12.01%
5 Industrials 9.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RVSB icon
951
Riverview Bancorp
RVSB
$107M
$169K ﹤0.01%
20,538
+1,788
+10% +$13.4K
NPKI
952
NPK International
NPKI
$1.21B
$167K ﹤0.01%
+26,661
New +$174K
LJPC
953
DELISTED
La Jolla Pharmaceutical Company
LJPC
$164K ﹤0.01%
+41,655
New +$246K
ALDX icon
954
Aldeyra Therapeutics
ALDX
$91.7M
$162K ﹤0.01%
+27,832
New +$161K
SYNC
955
DELISTED
Synacor, Inc.
SYNC
$162K ﹤0.01%
106,882
WTI icon
956
W&T Offshore
WTI
$545M
$161K ﹤0.01%
29,000
-21,100
-42% -$93.9K
CAMP
957
DELISTED
CalAmp Corp.
CAMP
$160K ﹤0.01%
728
+45
+7% +$11K
ASPN icon
958
Aspen Aerogels
ASPN
$387M
$155K ﹤0.01%
19,951
IDYA icon
959
IDEAYA Biosciences
IDYA
$3.41B
$151K ﹤0.01%
+20,118
New +$144K
LYTS icon
960
LSI Industries
LYTS
$853M
$148K ﹤0.01%
24,485
+100
+0.4% +$550
AQST icon
961
Aquestive Therapeutics
AQST
$462M
$146K ﹤0.01%
25,066
-89,145
-78% -$464K
SHLO
962
DELISTED
Shiloh Industries Inc
SHLO
$143K ﹤0.01%
40,188
+20,065
+100% +$77.3K
INFI
963
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$134K ﹤0.01%
139,453
-11,683
-8% -$12.8K
ENT
964
DELISTED
Global Eagle Entertainment Inc.
ENT
$134K ﹤0.01%
10,750
-607
-5% -$8.34K
MACK
965
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$133K ﹤0.01%
42,306
LFCR icon
966
Lifecore Biomedical
LFCR
$162M
$131K ﹤0.01%
+11,588
New +$123K
YELL
967
DELISTED
Yellow Corporation Common Stock
YELL
$131K ﹤0.01%
+51,205
New +$176K
LEE icon
968
Lee Enterprises
LEE
$166M
$125K ﹤0.01%
8,818
+3,684
+72% +$65.7K
PMBC
969
DELISTED
Pacific Mercantile Bancorp
PMBC
$124K ﹤0.01%
+15,246
New +$112K
FTSI
970
DELISTED
FTS International, Inc. Common Stock
FTSI
$118K ﹤0.01%
+5,654
New +$152K
AIRG icon
971
Airgain
AIRG
$74.3M
$116K ﹤0.01%
+10,850
New +$114K
TLRD
972
DELISTED
Tailored Brands, Inc.
TLRD
$114K ﹤0.01%
+27,489
New +$129K
ALSK
973
DELISTED
Alaska Communications Systems
ALSK
$112K ﹤0.01%
63,257
-189
-0.3% -$325
QUAD icon
974
Quad
QUAD
$430M
$111K ﹤0.01%
+23,716
New +$148K
SCPH
975
DELISTED
scPharmaceuticals
SCPH
$101K ﹤0.01%
17,791
+3,157
+22% +$16.2K

Similar funds

Jacobs Levy Equity Management's Q4 2019 Portfolio in Review

As of Q4 2019, Jacobs Levy Equity Management held 1,109 positions worth $10.2B, up 25% from $8.15B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Jacobs Levy Equity Management deployed $1.34B of net new capital in Q4 2019, opening 201 new positions and adding to 523 existing holdings. Its largest new stake was Athene Holding Ltd. Class A Common Shares: 551,505 shares worth $25.9M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Qualcomm, an estimated $76.7M trimmed.

  • Jacobs Levy Equity Management's largest Q4 2019 buy was Athene Holding Ltd. Class A Common Shares: 551,505 shares worth $25.9M.
  • Jacobs Levy Equity Management added most to AbbVie in Q4 2019, an estimated $57.2M increase.
  • Jacobs Levy Equity Management's biggest Q4 2019 reduction was Qualcomm, cutting an estimated $76.7M.
  • Jacobs Levy Equity Management fully exited NVR in Q4 2019, selling an estimated $49.7M.
  • Jacobs Levy Equity Management's ten largest holdings make up 17% of its $10.2B portfolio in Q4 2019.
  • Jacobs Levy Equity Management opened 201 new positions and closed 122 in Q4 2019.
  • Jacobs Levy Equity Management's portfolio value rose 25% quarter-over-quarter to $10.2B.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2019, filed 14 Feb 2020.